Panel Backs Pfizer’s Tofacitinib For RA, With Narrower Indication

FDA’s Arthritis Advisory Committee said May 9 that Pfizer had worded the second-line indication too broadly, and indicated that a 5 mg dose is to be preferred, at least to begin with, due to safety concerns.